Avoid the hype – how to successfully implement AI in drug discovery
AI has the potential to transform discovery. However, to ensure real impact, there are several practicalities that organisations must consider…
A practical guide to implementing AI
In this ebook, you’ll discover the key considerations which every leader needs to take in order to successfully implement AI in their drug discovery pipelines.
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
Optibrium demonstrates accelerated lead optimisation in complex agrochemical development
Optibrium’s QuanSA 3D-QSAR method uses an active learning approach to successfully and more efficiently identify a mimic of a macrocyclic natural product
Cerella case studies ebook
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
Meet with us at ACS Fall 2024
Join Daniel Barr to hear more about how deep learning imputation prioritises the most relevant data, accounts for uncertainty, and guides experiment selection to bring additional value to small molecule discovery.
38th ACS National Medicinal Chemistry Symposium
Join Optibrium’s Chris Khoury at the 38th NMCS meeting in Seattle, 23-26 June
AI in drug discovery – HubXchange
Join Optibrium at HubXchange in Boston to hear more about implementing AI in drug discovery.
How to be a great drug discovery chemist ebook
Discover the skills, knowledge and tools which are essential for success for today’s drug hunters.
Optibrium introduces cloud-based version of StarDrop drug discovery platform
Cloud-based version of StarDrop retains all the functionality and interactivity of desktop version with improved accessibility and lower total cost of ownership for customers.
Augmenting Inspiration with generative chemistry
Out now in International Biopharmaceutical Industry, Optibrium’s CEO, Dr Matt Segall introduces the concept of augmented intelligence. He explains how to use dynamic…
AI in the drug discovery industry
Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses…
Transforming drug discovery with deep learning imputation
In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares…
Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
Now, watch Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.
The power of AI applied to agrochemical bioactivity
In the face of growing agrochemical resistance and increasingly stringent regulatory requirements, how can artificial intelligence (AI) be harnessed to help lower the costs, failure rates and timelines associated with current agrochemical development cycles?
Transformative insights from your data in CDD vault with Cerella AI
In this webinar, learn about Cerella’s unique AI methods, see examples of its successful application throughout the drug discovery process and watch a demonstration of how CDD Vault and Cerella connect to seamlessly integrate with your workflows.
Perfecting the use of imperfect QSAR models
In this webinar, we examine the effective use of QSAR modelling in drug discovery and discuss a variety of pain points for medicinal chemists in knowing when a model can be trusted and how to avoid common pitfalls.
AI in early drug discovery: from promise to practice
In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry. Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.
AI Solutions from hit to candidate
In this webinar, we explore the highlights of collaborative project results that demonstrate how every phase of the drug discovery process can be radically improved by applying proven AI technology. Providing scientists with insights on which to base decisions can identify valuable new opportunities and reduce the time and cost of AI drug discovery cycles.
We review case studies from collaborations with Constellation Pharmaceuticals, AstraZeneca, Genentech, the University of Dundee and Takeda Pharmaceuticals to validate the impact of applying AI to experimental data and illustrate dramatic improvements to their project outcomes.
Join Samar Mahmoud and Matt Segall for this fascinating deep dive into the revolution that AI is bringing to the challenges of sparse and noisy drug discovery data.
